Pharvaris (PHVS) The Citizens Life Sciences Conference 2026 summary

Strategic vision and therapeutic focus

• Focused on hereditary angioedema (HAE) and broader bradykinin-mediated angioedema, aiming to address unmet needs with both prophylactic and on-demand oral therapies.

• Vision includes expanding to all forms of bradykinin-mediated angioedema and acquired angioedema, with ongoing trials in these areas.

• Differentiation is based on a mechanistic advantage, acting at the end of the bradykinin cascade, potentially covering multiple angioedema types.

• Pipeline considerations include exploring other bradykinin-mediated diseases beyond current indications.

Market evolution and opportunity

• HAE market has evolved from managing attacks to disease control, but significant unmet needs remain.

• Oral therapies are expected to dominate the on-demand segment due to convenience, speed, and patient preference.

• On-demand market estimated at $600 million in the US, about 20% of the total HAE market, with potential for further growth as more attacks are treated.

• About 53% of US on-demand treatments use icatibant; a more effective oral could shift market share and pricing dynamics.

Clinical development and data highlights

• Phase III on-demand data met primary and all 11 key secondary endpoints with statistical significance; time to initial symptom relief was 1.28 hours, and end of progression was 17.5 minutes.

• Data showed numerically better results than standard of care, with rapid and complete symptom resolution in less than 12 hours.

• Phase II prophylactic data showed 84.5% attack reduction, with open label extension reaching about 92%; phase III aims to replicate these results.

• Open label extension indicates high attack-free rates and strong patient interest in switching from other orals and injectables.